title: MicroRNA modulation in complex regional pain syndrome.
abstract: BACKGROUND
  Aberrant expression of small noncoding RNAs called microRNAs (miRNAs) is a common feature of several human diseases. The objective of the study was to identify miRNA modulation in patients with complex regional pain syndrome (CRPS) a chronic pain condition resulting from dysfunction in the central and/or peripheral nervous systems. Due to a multitude of inciting pathologies, symptoms and treatment conditions, the CRPS patient population is very heterogeneous. Our goal was to identify differentially expressed miRNAs in blood and explore their utility in patient stratification.
  
  
  METHODS
  We profiled miRNAs in whole blood from 41 patients with CRPS and 20 controls using TaqMan low density array cards. Since neurogenic inflammation is known to play a significant role in CRPS we measured inflammatory markers including chemokines, cytokines, and their soluble receptors in blood from the same individuals. Correlation analyses were performed for miRNAs, inflammatory markers and other parameters including disease symptoms, medication, and comorbid conditions.
  
  
  RESULTS
  Three different groups emerged from miRNA profiling. One group was comprised of 60% of CRPS patients and contained no control subjects. miRNA profiles from the remaining patients were interspersed among control samples in the other two groups. We identified differential expression of 18 miRNAs in CRPS patients. Analysis of inflammatory markers showed that vascular endothelial growth factor (VEGF), interleukin1 receptor antagonist (IL1Ra) and monocyte chemotactic protein-1 (MCP1) were significantly elevated in CRPS patients. VEGF and IL1Ra showed significant correlation with the patients reported pain levels. Analysis of the patients who were clustered according to their miRNA profile revealed correlations that were not significant in the total patient population. Correlation analysis of miRNAs detected in blood with additional parameters identified miRNAs associated with comorbidities such as headache, thyroid disorder and use of narcotics and antiepileptic drugs.
  
  
  CONCLUSIONS
  miRNA profiles can be useful in patient stratification and have utility as potential biomarkers for pain. Differentially expressed miRNAs can provide molecular insights into gene regulation and could lead to new therapeutic intervention strategies for CRPS.
authors.affiliation: Pharmacology & Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
authors.forename: Irina A
authors.initials: IA
authors.lastname: Orlova
authors.forename: Guillermo M
authors.initials: GM
authors.lastname: Alexander
authors.forename: Rehman A
authors.initials: RA
authors.lastname: Qureshi
authors.forename: Ahmet
authors.initials: A
authors.lastname: Sacan
authors.forename: Alessandro
authors.initials: A
authors.lastname: Graziano
authors.forename: James E
authors.initials: JE
authors.lastname: Barrett
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Schwartzman
authors.forename: Seena K
authors.initials: SK
authors.lastname: Ajit
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D020918:Complex Regional Pain Syndromes / Q000097:blood / Q000235:genetics*; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000235:genetics; D008297:Male; D035683:MicroRNAs / Q000097:blood / Q000235:genetics*; D008875:Middle Aged; D013223:Statistics as Topic
chemical_list: D015415:Biomarkers; D035683:MicroRNAs
references.citation: PLoS One. 2011 Mar 14;6(3):e17670
references.pmid: 21423802
references.citation: Mol Pain. 2007 Jun 08;3:15
references.pmid: 17559665
references.citation: Genome Res. 2009 Sep;19(9):1639-45
references.pmid: 19541911
references.citation: Trends Immunol. 2005 Oct;26(10):529-34
references.pmid: 16099720
references.citation: Clin J Pain. 2006 Mar-Apr;22(3):235-9
references.pmid: 16514322
references.citation: Cell. 2005 Jan 14;120(1):15-20
references.pmid: 15652477
references.citation: Pharmacol Ther. 2011 Apr;130(1):26-37
references.pmid: 21256154
references.citation: Oncogene. 2009 Jan 15;28(2):195-208
references.pmid: 18836484
references.citation: J Pain. 2012 Jan;13(1):10-20
references.pmid: 22172450
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5473-7
references.pmid: 19706812
references.citation: J Neurosci. 2010 Aug 11;30(32):10860-71
references.pmid: 20702715
references.citation: Clin Chem. 2010 Nov;56(11):1733-41
references.pmid: 20847327
references.citation: Neurology. 2007 Jul 3;69(1):42-9
references.pmid: 17606879
references.citation: Clin J Pain. 2009 May;25(4):273-80
references.pmid: 19590474
references.citation: PLoS One. 2008 Sep 05;3(9):e3148
references.pmid: 18773077
references.citation: Pain. 2007 Nov;132(1-2):195-205
references.pmid: 17890011
references.citation: Exp Hematol. 2010 Dec;38(12):1126-30
references.pmid: 20977925
references.citation: Expert Rev Neurother. 2006 May;6(5):669-81
references.pmid: 16734515
references.citation: Urol Oncol. 2010 Nov-Dec;28(6):655-61
references.pmid: 19375957
references.citation: Nat Cell Biol. 2011 Apr;13(4):423-33
references.pmid: 21423178
references.citation: Annu Rev Neurosci. 2009;32:1-32
references.pmid: 19400724
references.citation: Expert Opin Biol Ther. 2009 Jun;9(6):703-711
references.pmid: 19426115
references.citation: Biochem Soc Trans. 2011 Apr;39(2):482-6
references.pmid: 21428924
references.citation: Pain. 2001 Feb 1;90(1-2):1-6
references.pmid: 11166964
references.citation: Nat Rev Drug Discov. 2003 Jul;2(7):566-80
references.pmid: 12838269
references.citation: Mediators Inflamm. 2002 Feb;11(1):47-51
references.pmid: 11930962
references.citation: Br J Cancer. 2011 Mar 29;104(7):1168-77
references.pmid: 21407217
references.citation: Clin Exp Immunol. 2011 Apr;164(1):108-17
references.pmid: 21303362
references.citation: Eur J Neurol. 2010 May;17(5):649-60
references.pmid: 20180838
references.citation: J Neuroimmunol. 2010 Dec 15;229(1-2):26-50
references.pmid: 20870295
references.citation: Eur J Clin Pharmacol. 2006 Feb;62(2):91-5
references.pmid: 16344921
references.citation: Neuroscience. 2009 Dec 1;164(2):711-23
references.pmid: 19699278
references.citation: EMBO J. 2011 Jul 29;30(18):3830-41
references.pmid: 21804529
references.citation: Pain Med. 2007 May-Jun;8(4):326-31
references.pmid: 17610454
references.citation: Nat Protoc. 2008;3(6):1101-8
references.pmid: 18546601
references.citation: Gene. 2011 Jul 1;480(1-2):34-41
references.pmid: 21397669
references.citation: Eur J Pain. 2011 Sep;15(8):801.e1-12
references.pmid: 21397537
references.citation: Nat Rev Neurosci. 2005 Jul;6(7):521-32
references.pmid: 15995723
references.citation: Nat Rev Drug Discov. 2003 Dec;2(12):973-85
references.pmid: 14654796
references.citation: Mutat Res. 2011 Dec 1;717(1-2):85-90
references.pmid: 21402084
references.citation: Cell. 2009 Jan 23;136(2):215-33
references.pmid: 19167326
references.citation: Mol Pain. 2011 Mar 07;7:17
references.pmid: 21385380
references.citation: Cell Res. 2008 Oct;18(10):997-1006
references.pmid: 18766170
references.citation: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
references.pmid: 18663219
references.citation: Nat Methods. 2006 Nov;3(11):881-6
references.pmid: 17060911